Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening.
AMP-Activated Protein Kinase Restricts IFN-γ Signaling.
Endogenous opioids regulate the expression of inducible nitric oxide synthase by splenocytes.
Mutations affecting segment number and polarity in Drosophila.
Teva to initiate third Phase III trial of oral laquinimod for the treatment of relapsing remitting multiple sclerosis
Correlation between demyelinating lesions and executive function decline in a sample of Mexican patients with multiple sclerosis.
Corpus Callosum Atrophy - A Simple Predictor of Multiple Sclerosis Progression: A Longitudinal 9-Year Study.
Painful Tonic Spasm in Neuromyelitis Optica: Incidence, Diagnostic Utility, and Clinical Characteristics.
Direct angiotensin AT2-receptor stimulation attenuates T-cell and microglia activation and prevents demyelination in experimental autoimmune encephalomyelitis in mice.
[Vitamin D for prevention of diseases?].
Association of SNPs rs6498169 and rs10984447 with multiple sclerosis in Saudi Patients: a model of the usefulness of familial aggregates in identifying genetic linkage in a multifactorial disease.
Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve
Concurrent saturation transfer contrast in in vivo brain by a uniform magnetization transfer MRI.
Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO.
Platelets provide a bounty of potential targets for therapy in multiple sclerosis.
miR-15a and 16-1 are downregulated in CD4(+) T cells of multiple sclerosis relapsing patients.
The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures.
Ampyra 10mg beats 5mg, but weak overall results net neutral for ACOR
Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter.
Assessing walking disability in multiple sclerosis.
Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: An open-label study.
Reward responsiveness and fatigue in multiple sclerosis.
Novartis updates US label on Gilenya® following discussions with the FDA
Interferon beta 1a-induced severe autoimmune hepatitis in patients with multiple sclerosis: report of two cases and review of the literature.
Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates.

Pages